Toronto, May 25, 2026, 13:08 EDT
Cardiol Therapeutics’ Toronto-listed shares edged higher on Monday while the company’s Nasdaq stock did not trade for Memorial Day, leaving investors to weigh last week’s U.S. close against an approaching trial-enrollment deadline.
The TSX-listed shares were quoted at C$1.84, up 1.1%, at 11:39 a.m. Eastern, after trading between C$1.84 and C$1.89. Volume was thin at just over 8,300 shares by that quote.
This matters now because Cardiol straddles two markets. Nasdaq listed May 25 as a closed session for Memorial Day, while Canada’s CDS holiday schedule showed Canadian exchanges open on the U.S. holiday, with special settlement handling.
Last week was tidy, not dramatic. Public.com listed U.S. regular-session closes of $1.28, $1.26, $1.30, $1.32 and $1.32 for May 18 through May 22; StockAnalysis put Friday’s Nasdaq close at $1.32, up 0.76%, with volume of about 281,000 shares.
The broader Canadian tape helped the tone. Canada’s main S&P/TSX Composite Index rose to a record high on Monday, up 0.7% at 34,778.98 points at 10:21 a.m. ET, led by materials stocks, Reuters reported. Brian Madden, chief investment officer at First Avenue Investment Counsel, told Reuters that “even a non-zero chance” of an end to the U.S.-Iran conflict was enough to push stocks higher and oil lower. Reuters
For Cardiol, the stock case still sits on MAVERIC, its Phase III trial of CardiolRx in recurrent pericarditis. Phase III means a late-stage human study generally used to support a drug-approval request. Cardiol said in April that MAVERIC had reached 75% enrollment, was designed to enroll about 110 patients, and that target recruitment was expected by the end of the second quarter, with a possible extension into the third quarter if new sites add patients. Chief Executive David Elsley said the site expansion reflected “strong interest” and “investigator conviction” from U.S. clinical centers. Cardiol Therapeutics
Recurrent pericarditis is repeated inflammation of the sac around the heart, often causing chest pain, fatigue and shortness of breath. Earlier this month, Cardiol said Phase II MAvERIC results had been accepted for publication in the Journal of the American Heart Association; Elsley said the publication offered “important independent validation” and supported CardiolRx as a “non-immunosuppressive” therapy, meaning a treatment not designed to broadly suppress immune defenses. Cardiol Therapeutics
The balance sheet gives the company some room, but not a free pass. Cardiol reported C$27.7 million in cash and cash equivalents at March 31, up from C$21.4 million at year-end, while its first-quarter net loss widened to C$10.8 million from C$8.3 million a year earlier as research and development spending rose.
Management said in its quarterly filing that the March 31 cash balance should fund operations and planned milestones into the fourth quarter of 2027. Cash runway means the period a company says it can keep operating before it needs more financing, assuming its plans and costs hold.
The week ahead looks light on scheduled company events. Cardiol’s investor calendar listed no upcoming events after its May 19 H.C. Wainwright BioConnect fireside chat, so traders are likely to focus on any trial-enrollment update, filings, or movement when Nasdaq trading resumes.
The competitive frame is not empty. Kiniksa Pharmaceuticals’ Arcalyst, a weekly injected rilonacept therapy, is FDA-approved for recurrent pericarditis and reduction in recurrence risk in adults and children 12 and older; Kiniksa has described it as the first and only FDA-approved therapy for that use. That leaves Cardiol trying to prove an oral candidate can matter in a market with an incumbent.
But this remains a clinical-trial stock, and the downside path is plain enough. Cardiol itself lists risks including trial delays, negative or unclear study results, the need for additional financing, a history of losses and possible share dilution; any one of those could outweigh a modest TSX gain or a broad market rally.
For now, Monday’s move is more positioning than verdict. The next harder test is not a one-cent quote change. It is whether Cardiol can finish enrollment, keep spending within its stated runway, and produce data strong enough to support a New Drug Application, the formal request for U.S. Food and Drug Administration approval.
